Drug Profile

Research programme: fibrotic disease therapeutics - Alentis Therapeutics

Latest Information Update: 28 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator INSERM; The Mount Sinai Hospital; University of Strasbourg
Developer Alentis Therapeutics
Class Antifibrotics; Antineoplastics; Hepatoprotectants; Immunotherapies; Monoclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Aug 2024 No recent reports of development identified for preclinical development in Renal-fibrosis in Switzerland (Parenteral)
29 Jul 2020 Preclinical trials in Renal fibrosis in Switzerland (Parenteral)
30 Apr 2019 ALENTIS Therapeutics in-licenses platform technologies and monoclonal antibodies from University of Strasbourg, the Mount Sinai Hospital and INSERM prior to April 2019

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com